Merck Patent Gmbh

Michael Busch

Oliver Schadt

Markus Klein

Oliver Poeschke

Philipp Haselmayer

Dieter Dorsch

Guenter Hoelzemann

Ansgar Wegener

Kai Schiemann

Wolfgang Staehle

Jeyaprakashnarayanan Seenisamy

Dirk Wienke

Christa Burger

Compounds of formula (I) are inhibitors of LMP7 and can be employed, inter alia, for the treatment of an autoimmune disorder or hematological malignancies. 

Boronic acid derivatives

Substituted boronic acids and boronate esters as immunoproteasome inhibitors

Compounds of the formula I in which X, Y, Q, M, Qand B have the meanings indicated in Claim, are inhibitors of GCN2, and can be employed, inter alia, for the treatment of cancer.

Macrocycles as kinase inhibitors

Compounds of the formula I in which X, Rand Rhave the meanings indicated in Claimare inhibitors of GCN2, and can be employed, inter alia, for the treatment of cancer.

Imidazopyrimidine derivatives

The invention provides novel substituted benzyl piperidine compounds according to Formula (I) as lysophosphatidic acid (LPA) receptor antagonists, their manufacture and use for the treatment of proliferative or inflammatory diseases, such as cancer, fibrosis or arthritis.

Benzyl piperidine compounds as lysophosphatidic acid (LPA) receptor antagonist

Growing community of inventors

Darmstadt, Germany

Michael Busch